Trademark: NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io
Mark Identification
NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
Click here to search for trademarks similar to NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
Proof of use for NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
We do not have any records of a proof of use for NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES at this moment.
Click here to add a proof of use for NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
Possible trademark infringements of NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
Basic Information about NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
- Serial Number
- 88730797
- Filing Date
- 17 Dec 2019
- Mark Drawing Code
- 4
Classifications
Declare the trademark use of NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES on the blockchain with WikiTrademarks.io.
- First use of NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES anywhere
- NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES was first used on 10 Jan 2020 for the primary classification of goods and services, international, 042 (Computer, scientific & legal)
- First use in commerce
- There is no first use of this trademark in commerce detected yet.
- Status Code
- 6
- International Code
- 042
- US Codes
- 100; 101
Who owns NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES?
1. Angiex, Inc. Cambridge MA
Correspondent
- Susanna P. Lichter
- WILSON SONSINI GOODRICH & ROSATI
- 650 PAGE MILL ROAD
- PALO ALTO CA 94304-1050
Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io